Human CD80/CD86 Double Knockout Cell Line-HEK293T
Cat.No. : CSC-RT2786
Host Cell: HEK293T Target Gene: CD80, CD86
Size: 1x10^6 cells/vial, 1mL Validation: Sequencing
Inquire for Price
Cell Line Information
Cell Culture Information
Safety and Packaging
| Cat. No. | CSC-RT2786 |
| Cell Line Information | This cell is a stable cell line with a homozygous knockout of CD80 and CD86 using CRISPR/Cas9. |
| Target Gene | CD80, CD86 |
| Host Cell | HEK293T |
| Size Form | 1 vial (>10^6 cell/vial) |
| Shipping | Dry ice package |
| Storage | Liquid Nitrogen |
| Species | Human |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Media Type | Cells were cultured in DMEM supplemented with 10% fetal bovine serum. |
| Growth Properties | Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Split at 80-90% confluence, approximately 1:3-1:6. |
| Freeze Medium | Complete medium supplemented with 10% (v/v) DMSO |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
Inquiry
Background
Applications
CD80, also known as B7-1, is mainly expressed on antigen presenting cells (APCs), such as dendritic cells, activated B cells, and macrophages. It works closely with another B7 family member, CD86 (B7-2). CD80 contains 288 amino acids and has a molecular weight of 33 kDa. Structurally, it contains two extracellular immunoglobulin-like domains, a transmembrane segment, and a short cytoplasmic tail. CD80 exists in monomeric and dimer forms, but it mainly forms dimers. CD80 binds to CD28 and promotes T-cell activation and proliferation by providing essential co-stimulatory signals. In contrast, binding to CTLA-4 transmits inhibitory signals to attenuate T-cell activity, thus playing a key checkpoint role in immune regulation.
CD86, also known as B7-2, is another co-stimulatory molecule expressed on various APCs, including dendritic cells, Langerhans cells, macrophages, and B cells. It shares similarities with CD80, including its structure and function in the immune system. CD86 is 329 amino acids long and is a 70 kDa glycoprotein. Structurally, CD86 contains an Ig-like extracellular domain, a transmembrane region, and a longer cytoplasmic domain compared to CD80. CD86 is essential for the initial activation of T cells and is more abundantly expressed and more rapidly induced after activation than CD80. Like CD80, CD86 interacts with CD28 to provide the necessary co-stimulatory signals for naive T cell activation and interacts with CTLA-4 to transmit inhibitory signals, thereby regulating immune responses.
Human CD80/CD86 Double Knockout Cell Line - HEK293T has been precisely genetically engineered to eliminate the expression of CD80 (B7-1) and CD86 (B7-2). These proteins play a crucial role in immune responses, acting as ligands for CD28 and CTLA-4 on T cells, thereby regulating T cell activation and tolerance. The following are the main applications of this double knockout cell line:
Immunology Research: The lack of CD80/CD86 expression allows researchers to dissect the specific contributions of these molecules in immune synapse formation and T cell receptor signaling pathways.
Cancer Research: In oncology, CD80/CD86 double knockout cells can help study the mechanisms of tumor immune evasion. By studying the interaction between T cells and these modified HEK293T cells, researchers can develop targeted therapies designed to enhance anti-tumor immunity.
Drug Discovery and Development: This cell line provides a valuable platform for screening potential immunotherapeutic agents. Compounds that modulate pathways involving CD80 and CD86 can be tested for efficacy and safety, aiding the development of new drugs for autoimmune diseases and cancer.
Vaccine Development: Understanding how antigen presenting cells interact with T cells is critical for vaccine efficacy. This double knockout cell line can be used to study the adjuvant properties and effectiveness of various vaccine components in the absence of these co-stimulatory signals.
Cell Therapy Research: The CD80/CD86 double knockout cell line can be used to develop and optimize cell-based therapies, including adoptive T cell transfer and CAR-T cell therapy. By providing a controlled environment, manipulation and understanding of T cell activation can be improved for therapeutic purposes.
For research use only. Not intended for any clinical use.
